Plain-English translation of NCT07036601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether an injection called THDBH120 can help people who are overweight or obese lose weight. Participants will receive either the new medication or a placebo (a dummy injection with no active ingredient) and their weight loss will be measured over 26 weeks. Researchers want to understand if this treatment is safe and effective for weight reduction.
Current weight loss treatments don't work for everyone, and some people struggle to lose weight through diet and exercise alone. This trial is exploring whether this new medication could offer another option for people who have tried diet and exercise but need additional help.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic for screening and baseline tests, then receive either the injection or a placebo regularly over 26 weeks. During that time, you'll have follow-up visits to check your weight, health, and how you're responding to the treatment. Researchers will monitor your safety throughout with blood tests and heart rhythm checks.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
China
Testing effectiveness
Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Enrollment target
~276 participants
Started
January 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.